Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision

References

• Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 103, 281–300 (1980).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46, 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343(20), 1430–1438 (2000).
   PubMed Web of Science ®Google Scholar
• Kornek B, Lassmann H. Neuropathology of multiple sclerosis – new concepts. Brain Res. Bull. 61(3), 321–326 (2003).
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon–β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45, 1277–1285 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology 45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268), 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N. Engl. J. Med. 343, 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2), 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58(6), 840–846 (2005).
   PubMedGoogle Scholar
• Filippi M, Rovaris M, Inglese M et al. Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364, 1489–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346(3), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60(1), 27–30 (2003).
   PubMed Web of Science ®Google Scholar
• Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch. Ophthalmol. 113(2), 136–137 (1995).
   PubMedGoogle Scholar
• Morrissey SP, Miller DH, Kendall BE et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116, 135–146 (1993).
   PubMedGoogle Scholar
• O’Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121, 495–503 (1998).
   PubMed Web of Science ®Google Scholar
• Ramsaransing G, Maurits N, Zwanikken C, De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult. Scler. 7(5), 345–347 (2001).
   PubMedGoogle Scholar
• Pittock SJ, McClelland RL, Mayr WT et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann. Neurol. 56(2), 303–306 (2004).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770–782 (2003).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GPA et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112, 133–146 (1989)
   PubMedGoogle Scholar
• Schumacher GA, Beebe GW, Kibler RF et al. Problems of experimental trials of therapy in MS: report by the panel of the evaluation of experimental trials of therapy in MS. Ann. NY Acad. Sci. 122, 552–568 (1965).
   Google Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 116, 117–134 (1993).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. Natural history of multiple sclerosis. Ann. Neurol. 36(Suppl.) S6–S11 (1994).
   PubMed Web of Science ®Google Scholar
• Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP. Factors associated with a rapid course of multiple sclerosis. Arch. Neurol. 39, 337–341 (1982).
   PubMed Web of Science ®Google Scholar
• Wolfson C, Confavreux C. Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short term prognosis. Neuroepidemiology 6, 101–115 (1987).
   PubMedGoogle Scholar
• Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Basekerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114, 1057–1067 (1991).
   PubMed Web of Science ®Google Scholar
• Trojano M, Avolio C, Manzari C et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J. Neurol. Neurosurg. Psychiatry 58, 300–306 (1995).
   PubMedGoogle Scholar
• Phadke JC. Clinical aspect of multiple sclerosis in North East Scotland with particular reference to its course and prognosis. Brain 113, 1597–1628 (1990).
   PubMed Web of Science ®Google Scholar
• Lauer K, Firnhaber W. Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study. J. Neurol. 239, 93–97 (1992).
   PubMedGoogle Scholar
• Kantarci O, Siva A, Eraksoy M et al. Survival and predictors of disability in Turkish MS patients. Neurology 51, 765–772 (1998).
   PubMedGoogle Scholar
• Bergamaschi R, Montomoli C, Candeloro E, Fratti C, Citterio A, Cosi V. Disability and mortality in a cohort of multiple sclerosis patients: a reappraisal. Neuroepidemiology 25(1), 15–18 (2005).
   PubMedGoogle Scholar
• Broman T, Andersen O, Bergmann L. Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol. Scand. 63(1), 6–33 (1981).
   PubMedGoogle Scholar
• Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol. Scand. 70, 321–328 (1984).
   PubMedGoogle Scholar
• Riise T, Gronnig M, Fernandez O et al. Early prognostic factors for disability in multiple sclerosis: a European multicenter study. Acta Neurol. Scand. 85, 212–218 (1992).
   PubMedGoogle Scholar
• Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J. Neurol. Sci. 168, 96–106 (1999).
   PubMed Web of Science ®Google Scholar
• Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS. Comparison with adult-onset forms. Neurology 59, 1922–1928 (2002).
   PubMed Web of Science ®Google Scholar
• Levic ZM, Dujmovic I, Pekmezovic T et al. Prognostic factors for survival in multiple sclerosis. Mult. Scler. 5, 171–178 (1999).
   PubMedGoogle Scholar
• Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339 (5), 285–291 (1998).
   PubMed Web of Science ®Google Scholar
• Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-κ B. J. Neuroimmunol. 124(1–2), 106–114 (2002).
   PubMedGoogle Scholar
• Falaschi P, Martocchia A, Proietti A, D’Urso R, Antonini G. High incidence of hyperandrogenism-related clinical signs in patients with multiple sclerosis. Neuro. Endocrinol. Lett. 22(4), 248–250 (2001).
   PubMedGoogle Scholar
• Drew PD, Chavis JA. Female sex steroids: effects upon microglial cell activation. J. Neuroimmunol. 111(1–2), 77–85 (2000).
   PubMed Web of Science ®Google Scholar
• Cardona-Gomez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia-Segura LM. Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res. Brain Res. Rev. 37(1–3), 320–334 (2001).
   PubMedGoogle Scholar
• Smith ME, Eller NL, McFarland HF, Racke MK, Raine CS. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am. J. Pathol. 155(4), 1147–1161 (1999).
   PubMedGoogle Scholar
• Huseby ES, Sather B, Huseby PG, Goverman J. Age-dependent T cell tolerance and autoimmunity to myelin basic protein. Immunity 14(4), 471–481 (2001).
   PubMed Web of Science ®Google Scholar
• Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol. Scand. 66, 355–362 (1982).
   PubMed Web of Science ®Google Scholar
• Noseworthy J, Paty D, Wonnacott T, Feasby T, Ebers G. Multiple sclerosis after age 50. Neurology 33(12), 1537–1544 (1983).
   PubMedGoogle Scholar
• Thompson AJ, Hutchinson M, Brazil J et al. A clinical and laboratory study of benign multiple sclerosis. Q. J. Med. New Ser. 58, 69–80 (1986).
   PubMedGoogle Scholar
• Trojano M, Liguori, Zimatore GB et al. Age-related disability in multiple sclerosis. Ann. Neurol. 51, 475–480 (2002).
   PubMedGoogle Scholar
• Citterio A, Azan G, Bergamaschi R, Erbetta A, Cosi V. Multiple sclerosis: disability and mortality in a cohort of clinically diagnosed patients. Neuroepidemiology 8, 249–253 (1989).
   PubMedGoogle Scholar
• Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch. Neurol. 53, 353–358 (1996).
   PubMedGoogle Scholar
• Mathews WB. Symptoms and signs. In: McAlpine’s Multiple Sclerosis. Mathews WB, Compston A, Allen IV et al. (Eds), Churchill Livingstone, NY, USA, 43–77 (1991).
   Google Scholar
• Kraft GH, Freal JE, Coryell JK, Hanan CL, Chitnis N. Multiple sclerosis: early prognostic guidelines. Arch. Phys. Med. Rehabil. 62(2), 54–58 (1981).
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Suissa S, Vallee L et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 144(2), 246–252 (2004).
   PubMed Web of Science ®Google Scholar
• Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J. Neurol. 252(Suppl. 3), 15–20 (2005).
   Google Scholar
• Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research. An introduction to Bayesian methods in health technology assessment. Br. Med. J. 319, 508–512 (1999).
   PubMed Web of Science ®Google Scholar
• Berzuini C, Larizza C. A unified approach for modelling longitudinal and failure time data, with application in medical monitoring. IEEE Trans Patt. An. Mach. Intell. 2, 109–123 (1996).
   Google Scholar
• Bergamaschi R, Romani A, Tonietti S, Citterio A, Berzuini C, Cosi V. Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis. Neurol. Sci. 21(4 Suppl. 2), S819–S823 (2000).
   Google Scholar
• Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis. J. Neurol. Sci. 189, 13–21 (2001).
   PubMed Web of Science ®Google Scholar
• Brex PA, O’Riordan JI, Miszkiel KA et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53(6), 1184–1190 (1999).
   PubMedGoogle Scholar
• Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch. Neurol. 61(2), 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• O’Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121(3), 495–503 (1998).
   PubMed Web of Science ®Google Scholar
• Filippi M, Horsfield MA, Morrissey SP et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44(4), 635–641 (1994).
   PubMedGoogle Scholar
• Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(11), 2059–2069 (1997).
   PubMed Web of Science ®Google Scholar
• Santos AC, Narayanan S, de Stefano N et al. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J. Neurol. 249(6), 662–668 (2002).
   PubMed Web of Science ®Google Scholar
• Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 58(12), 2044–2045 (2001).
   PubMedGoogle Scholar
• Hume AL, Waxman SG. Evoked potentials in suspected multiple sclerosis: diagnostic value and prediction of clinical course. J. Neurol. Sci. 83, 191–210 (1988).
   PubMedGoogle Scholar
• Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124(11), 2162–2168 (2001).
   PubMedGoogle Scholar